{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:51:25Z","timestamp":1790790685616,"version":"4.1.0"},"reference-count":34,"publisher":"American Society for Clinical Investigation","issue":"21","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,1]]},"DOI":"10.1172\/jci186744","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T14:00:38Z","timestamp":1730383238000},"source":"Crossref","is-referenced-by-count":18,"title":["Hidradenitis suppurativa: key insights into treatment success and failure"],"prefix":"10.1172","volume":"134","author":[{"given":"Kelsey R.","family":"van Straalen","sequence":"first","affiliation":[{"name":"Laboratory for Experimental Immunodermatology, Department of Dermatology, Erasmus University Medical Center, Rotterdam, Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Piguet","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada."},{"name":"Division of Dermatology, Department of Medicine, Women\u2019s College Hospital, Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann E.","family":"Gudjonsson","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan, USA."},{"name":"Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA."},{"name":"Taubman Medical Research Institute, Ann Arbor, Michigan, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"232","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16101"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.02.003"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.139930"},{"key":"B4","unstructured":"Kimball AB, et al. Efficacy and safety of the oral Bruton\u2019s tyrosine kinase inhibitor, remibrutinib, in patients with moderate to severe hidradenitis suppurativa in a randomized, phase 2, double-blind, placebo-controlled platform study. Paper presented at the 2024 American Academy of Dermatology Meeting; March 8\u201312, 2024; San Diego, California, USA. https:\/\/am2024.aad.org\/sessions\/16895 Accessed September 18, 2024"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.05.076"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504370"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00022-3"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.139932"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljac007"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1177\/12034754231154261"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.07.187"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav5908"},{"key":"B13","unstructured":"van Dalen S, et al. Anti-citrullinated histone antibody CIT-013: Targeting neutrophil extracellular traps as an anti-inflammatory therapy in hidradenitis suppurativa. Paper present at the 13th Conference of the European Hidradenitis Suppurativa Foundation; Lyon, France; February 7\u20139, 2024. https:\/\/ehsf2024.com\/program\/scientific-program\/ Accessed September, 18, 2024"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.10.034"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.169870"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1172\/JCI169225"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0282763"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0279060"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.09.036"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15597"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/exd.15087"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19725"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00913-3"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19252"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00746-9"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28172-4"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.01.023"},{"key":"B28","unstructured":"AnaptysBio. AnaptysBio Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa. https:\/\/ir.anaptysbio.com\/news-releases\/news-release-details\/anaptysbio-reports-harp-phase-2-top-line-data-imsidolimab\/ Updated August 31, 2022. Accessed July 26, 2024"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae144"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.3903"},{"key":"B31","unstructured":"AbbVie. Lutikizumab Showed Positive Results in a Phase 2 Trial of Adults with Moderate to Severe Hidradenitis Suppurativa as Program Advances to Phase 3. https:\/\/news.abbvie.com\/2024-01-08-Lutikizumab-Showed-Positive-Results-in-a-Phase-2-Trial-of-Adults-with-Moderate-to-Severe-Hidradenitis-Suppurativa-as-Program-Advances-to-Phase-3 Updated January 8, 2024. Accessed July 26, 2024"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2300155"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.10.034"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.05.033"}],"container-title":["Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jci.org\/articles\/view\/186744\/files\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T22:59:29Z","timestamp":1779231569000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jci.org\/articles\/view\/186744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":34,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2024,11,1]]},"published-print":{"date-parts":[[2024,11,1]]}},"alternative-id":["10.1172\/JCI186744"],"URL":"https:\/\/doi.org\/10.1172\/jci186744","relation":{},"ISSN":["1558-8238"],"issn-type":[{"value":"1558-8238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,1]]},"article-number":"e186744"}}